News & Views

Read the latest RCOphth news updates and guidance here.

News

BOSU report shows patients losing sight to follow-up appointment delays

This research, conducted through the British Ophthalmological Surveillance Unit (BOSU), found patients suffering permanent and severe visual loss due to health service initiated delays1.  The research involving all UK consultant ophthalmologists, showed that up to 22 patients per month may be losing vision by such delays. These patients are from a vulnerable social group with chronic conditions requiring long-term routine follow-up such as glaucoma, age related macular degeneration and diabetic retinopathy.

Statement

Strabismus (squint) surgical intervention is not a cosmetic procedure

The College recognises that botulinum toxin and surgical treatment for strabismus* are important procedures that are performed in children and adults to promote, improve or re-establish binocular function, manage diplopia and restore ocular alignment and balance. Surgical intervention (including botulinum toxin injections) performed to achieve these aims is thus not a cosmetic procedure and does not fall under the GMC guidance for cosmetic surgery. Commissioning pathways for the management of squints reflect this. Surgical intervention (including botulinum toxin injections) performed to achieve these aims is thus not a cosmetic procedure and does not fall under the GMC guidance for cosmetic surgery. Commissioning pathways for the management of squints reflect this.

News

NEW Retinal Vein Occlusion (RVO) Guidelines July 2015

These guidelines (July 2015) reflect changes in treatments, since the 2010 Interim RVO Guidelines. The guidelines provide evidence-based, clinical advice for the management of different aspects of RVO. The scope is limited to current diagnostic tools, management and service set-up and delivery to facilitate delivery of optimal care.

News

New Guidelines for Thyroid Eye Disease

It is hoped that the Guidelines for Thyroid Eye Disease (2015) will facilitate early diagnosis and better treatment of patients with this disease. It is estimated that there are about 2,500 new cases of Thyroid Eye Disease (TED) every year in the UK. The figures have declined over the past 10-20 years for reasons that are unclear.

Statement

NICE guidance on Ocriplasmin

The Royal College of Ophthalmologists welcomes the decision by the National Institute for Health and Care Excellence (NICE) to recommend 125 micrograms Ocriplasmin intravitreal injection as an option for the treatment of vitreomacular traction (VMT) in adults who have either stage II full-thickness macular holes (FTMH) with a diameter of ≤ 400um and/or severe symptoms.